M. Karreman, J. Luime, J. Hazes, and A. Weel, The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, Journal of Crohn's and Colitis, p.199, 2016.
DOI : 10.1093/ecco-jcc/jjw199

S. Vavricka, A. Schoepfer, M. Scharl, P. Lakatos, A. Navarini et al., Extraintestinal Manifestations of Inflammatory Bowel Disease Inflamm Bowel Dis, pp.1982-92, 2015.

A. Thomas, Ocular manifestations of inflammatory bowel disease, Current Opinion in Ophthalmology, vol.27, issue.6, pp.552-560, 2016.
DOI : 10.1097/ICU.0000000000000310

J. Ko, Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years, Journal of Cutaneous Pathology, vol.105, issue.11, pp.946-955, 2016.
DOI : 10.1038/ajg.2010.124

S. Restellini, Hepatic manifestations of inflammatory bowel diseases, Liver International, vol.19, issue.5 Suppl
DOI : 10.3748/wjg.v19.i42.7327

D. Lu and X. Ji, Li HJ 1 , Zhang CQ 1 . Pulmonary manifestations of Crohn's disease, World J Gastroenterol Jan, vol.720, issue.1 11, pp.133-174, 2014.

Y. Chen and J. Su, Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study, Journal of Gastroenterology and Hepatology, vol.15, issue.4, pp.782-789
DOI : 10.1002/ibd.20898

H. Bedioui, A. Daghfous, O. Baraket, S. Chouaieb, L. Kallel et al., Acute peritonitis complicating Crohn's disease: epidemiologic and physiopathological characteristics, Tunis Med. Feb, vol.89, issue.2, pp.198-201, 2011.

R. Ennaifer, A. Ouakaa-kchaou, N. Belhadj, and H. Elloumi, Psoas abscess as the initial manifestation of Crohn's disease, 2009.

G. Li, J. Ren, G. Wang, Q. Wu, G. Gu et al., Prevalence and Risk Factors of Acute Lower Gastrointestinal Bleeding in Crohn Disease, Medicine, vol.94, issue.19, p.2015
DOI : 10.1097/MD.0000000000000804

E. Loftus, . Jr-1, and W. Sandborn, Epidemiology of inflammatory bowel disease, Gastroenterology Clinics of North America, vol.31, issue.1, pp.1-20, 2002.
DOI : 10.1016/S0889-8553(01)00002-4

S. Shavananda, J. Lennnard-jones, R. Logan, N. Fear, and P. A. Carpenter, Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)., Gut, vol.39, issue.5, pp.690-97, 1996.
DOI : 10.1136/gut.39.5.690

V. Nerich, E. Monnet, E. A. Louafi, S. Ramee, C. Rican et al., Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data, Inflammatory Bowel Diseases, vol.12, issue.3, pp.218-244, 2006.
DOI : 10.1097/01.MIB.0000206540.38834.8c

URL : https://hal.archives-ouvertes.fr/hal-00466309

A. Dupuy, J. Cosnes, J. Revuz, J. Delchier, J. Gendre et al., Oral Crohn Disease, Archives of Dermatology, vol.135, issue.4, 1999.
DOI : 10.1001/archderm.135.4.439

URL : http://archderm.jamanetwork.com/data/journals/derm/11685/dob8032.pdf

H. Jouin, R. Baumann, A. Abbas, B. Duclos, M. Weill-bousson et al., Esophagogastroduodenal localizations of Crohn's disease are frequent, Gastroenterol Clin Biol, vol.10, pp.8-9549, 1986.

H. Freeman, Long-Term Clinical Behavior of Jejunoileal Involvement in Crohn???s Disease, Canadian Journal of Gastroenterology, vol.19, issue.9, pp.575-583, 2005.
DOI : 10.1155/2005/647459

W. Harb, Crohn's Disease of the Colon, Rectum, and Anus Surg Clin North Am, pp.1195-210, 2015.

N. 1. Zwintscher, P. Shah, A. Argawal, P. Chesley, E. Johnson et al., The impact of perianal disease in young patients with inflammatory bowel disease, International Journal of Colorectal Disease, vol.103, issue.2, pp.1275-1284, 2015.
DOI : 10.1111/j.1572-0241.2008.02212.x

E. Langholz, P. Munkholm, O. Nielsen, S. Kreiner, and V. Binder, Incidence and Prevalence of Ulcerative Colitis in Copenhagen County from 1962 to 1987, Scandinavian Journal of Gastroenterology, vol.26, issue.158, pp.1247-56, 1991.
DOI : 10.1136/gut.26.2.158

Y. Huang, Inflammatory bowel disease related innate immunity and adaptive immunity, Am J Transl Res Jun, vol.158, issue.26, pp.2490-2497, 2016.

E. Legaki and M. Gazouli, Influence of environmental factors in the development of inflammatory bowel diseases, World Journal of Gastrointestinal Pharmacology and Therapeutics, vol.7, issue.1, pp.112-137
DOI : 10.4292/wjgpt.v7.i1.112

A. Abegunde and B. Muhammad, Environmental risk factors for inflammatory bowel diseases: Evidence based literature review, World Journal of Gastroenterology, vol.22, issue.27, pp.6296-317, 2016.
DOI : 10.1016/j.cell.2012.02.005

URL : http://doi.org/10.3748/wjg.v22.i27.6296

J. Opstelten and R. Beelen, Exposure to Ambient Air Pollution and the Risk of Inflammatory Bowel Disease: A European Nested Case???Control Study, Digestive Diseases and Sciences, vol.47, issue.10, pp.2963-71, 2016.
DOI : 10.1021/es4008849

S. Quezada and P. Langenberg, Tu1104 Cigarette Smoking Adversely Affects Disease Activity and Disease-Specific Quality of Life in Patients With Crohn's Disease (CD) Evaluated At Tertiary Referral Center, Gastroenterology, vol.144, issue.5, pp.307-310, 2016.
DOI : 10.1016/S0016-5085(13)62820-6

T. 1. Gardenbroek and T. Pinkney, The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019), BMC Surgery, vol.10, issue.1, pp.30-40, 2015.
DOI : 10.1111/j.1463-1318.2008.01477.x

J. Forbes, Van Domselaar G 1 , Bernstein CN 2 . The Gut Microbiota in Immune- Mediated Inflammatory Diseases. Front Microbiol, Jul, vol.117, 2016.

M. 1. Konikoff and L. Denson, Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.12, issue.6, 2006.
DOI : 10.1097/00054725-200606000-00013

F. S. Lehmann and E. Burri, and Christoph Beglinger The role and utility of faecal markers in inflammatory bowel disease Therap Adv Gastroenterol, pp.23-36, 2015.

A. Dignass, R. Eliakim, F. Magro, C. Maaser, Y. Chowers et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, 2012.
DOI : 10.1016/j.crohns.2012.09.003

J. Lee and K. Lee, Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease. Clin Endosc, 2016.

M. Luján-sanchis, L. Sanchis-artero, and L. Larrey-ruiz, Current role of capsule endoscopy in Crohn???s disease, World Journal of Gastrointestinal Endoscopy, vol.8, issue.17, pp.572-83, 2016.
DOI : 10.4253/wjge.v8.i17.572

G. Tontini, Rath T 1 , Neumann H Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases, World J Gastroenterol, vol.22, issue.3, 2016.
DOI : 10.3748/wjg.v22.i3.1246

URL : http://doi.org/10.3748/wjg.v22.i3.1246

R. Khanna, S. Nelson, B. Feagan, D. Haens, G. Sandborn et al., Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev, 2016.

G. Soucy, H. Helen, . Wang, A. Francis, . Farraye et al., Clinical and pathological analysis of colonic Crohn's disease, including a subgroup with ulcerative colitis-like features Modern Pathology, pp.295-307, 2011.

A. Bousvaros, D. Antonioli, R. Colletti, and M. Dubinsky, Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America, J Pediatr Gastroenterol Nutr, vol.44, issue.5, pp.653-74, 2007.

K. Schroeder, W. Tremaine, and D. Ilstrup, Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, New England Journal of Medicine, vol.317, issue.26, pp.1625-1634, 1987.
DOI : 10.1056/NEJM198712243172603

A. Rezaie, M. Kuenzig, E. Benchimol, and A. Griffiths, Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2015.

P. A. Feldman, M. D. , D. Wolfson, M. D. , J. S. Barkin et al., 1 Medical Management of Crohn's Disease Clin Colon Rectal Surg, pp.269-281, 2007.

E. Prefontaine, J. Macdonald, and L. Sutherland, Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2009.

S. Lichtiger, D. Present, A. Kornbluth, I. Gelernt, J. Bauer et al., Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

M. Mañosa, V. García, L. Castro, O. García-bosch, M. Chaparro et al., Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy, Journal of Crohn's and Colitis, vol.5, issue.5, pp.397-401, 2011.
DOI : 10.1016/j.crohns.2011.03.012

W. Sandborn, G. Van-assche, W. Reinisch, and J. Colombel, Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2011.
DOI : 10.1053/j.gastro.2011.10.032

S. Targan, S. Hanauer, S. Van-deventer, and L. Mayer, A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997.
DOI : 10.1056/NEJM199710093371502

W. Sandborn, PURSUIT-Maintenance Study Group Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, vol.146, issue.2 3 31, 2013.

X. Roblin, N. Williet, and L. Peyrin-biroulet, Thiopurine Metabolism in the Era of Combotherapy, Inflammatory Bowel Diseases, vol.22, issue.6, pp.1496-501
DOI : 10.1097/MIB.0000000000000737

D. Soler, T. Chapman, L. Yang, T. Wyant, R. Egan et al., The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 J Pharmacol Exp Ther, pp.864-75, 2009.

J. Colombel, Sandborn W 3 , et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut

J. Rahier, S. Ben-horin, Y. Chowers, C. Conlon, D. Munter et al., European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009.
DOI : 10.1016/j.crohns.2009.02.010

S. Riestra and F. , Saro C 3 et al. Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization, Rev Esp Enferm Dig, vol.2108, issue.29, pp.541-550, 2016.

L. Peyrin-biroulet, W. Sandborn, and B. Sands, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1338, 2015.
DOI : 10.1038/ajg.2012.117

URL : https://hal.archives-ouvertes.fr/hal-01191653

B. Feagan, P. Rutgeerts, and B. Sands, Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013.
DOI : 10.1056/NEJMoa1215734

W. Sandborn, B. Feagan, and P. Rutgeerts, Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease, New England Journal of Medicine, vol.369, issue.8, pp.711-721, 2013.
DOI : 10.1056/NEJMoa1215739

B. Sands, B. Feagan, and P. Rutgeerts, Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.
DOI : 10.1053/j.gastro.2014.05.008

R. Harvey and J. Bradshaw, A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980.
DOI : 10.1016/S0140-6736(80)92767-1

Y. Jin and Y. Lin, Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis, World Journal of Gastroenterology, vol.21, issue.20, pp.6352-6360, 2015.
DOI : 10.2147/BTT.S30416

A. Amiot, J. Grimaud, L. Peyrin-biroulet, J. Filippi, B. Pariente et al., on the behalf of the OBSERV-IBD study group and the GETAID, Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology

E. Shelton, J. Allegretti, and B. Stevens, Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients, Inflammatory Bowel Diseases, vol.21, issue.12, 2015.
DOI : 10.1097/MIB.0000000000000561

B. Feagan, D. Rubin, and S. Danese, Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to TNF Antagonist Clin Gastroenterol Hepatol, pp.1542-356530655, 2016.

A. Parikh, I. Fox, T. Leach, J. Xu, C. Scholz et al., Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.8, pp.1691-1700
DOI : 10.1097/MIB.0b013e318281f538

S. Vermeire, E. V. Loftus-jr, J. Colombel, B. G. Feagan, and W. J. Sandborn, Long-term Efficacy of Vedolizumab for Crohn???s Disease, Journal of Crohn's and Colitis
DOI : 10.1093/ecco-jcc/jjw176

V. Edward, J. Loftus-jr, and B. Colombel, Long-term Efficacy of Vedolizumab for Ulcerative Colitis J Crohns Colitis, p.177, 2016.

T. Sipponen, H. Nuutinen, U. Turunen, and M. Färkkilä, Endoscopic Evaluation of Crohn's Disease Activity comparison of the CDEIS and the SES-CD Inflamm Bowel Dis, pp.2131-2137, 2010.

S. Travis, D. Schnell, P. Krzeski, M. Abreu, and D. Altman, Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut, vol.61, issue.4, pp.535-577, 2012.
DOI : 10.1136/gutjnl-2011-300486

P. Dulai, Hartke J. 2 , Chilukuri P. et al. Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium

B. G. Feagan, H. Patel, J. Colombel, D. T. Rubin, A. James et al., Lasch Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

B. Feagan, G. Greenberg, and G. Wild, Integrin, New England Journal of Medicine, vol.352, issue.24, pp.2499-507, 2005.
DOI : 10.1056/NEJMoa042982

G. Fiorino, C. Correale, and W. Fries, Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease, Expert Review of Clinical Immunology, vol.6, issue.4, pp.567-572, 2010.
DOI : 10.2165/00063030-200822040-00005

M. Dubinsky, Uma Mahadevan; Severine Vermeire; Brihad Abhyankar; Karen Lasch Vedolizumab Exposure in Pregnancy : Outcomes From Clinical Studies in Inflammatory Bowel Disease

W. Sandborn-*-1 and J. , Colombel 2 , R. Panaccione 3 , K. Lasch 4 , R. Mody 5 , A. Green 6 , B. Abhyankar 7 Deep remission as a predictor of clinical outcomes in vedolizumabtreated patients with ulcerative colitis

W. J. Sandborn, M. D. , C. Gasink, and M. D. , for the CERTIFI Study Group: Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

M. Jacqueline, D. Benson, . Perritt, J. Bernard, and . Scallon, Discovery and mechanism of ustekinumab, a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders MAbs, pp.535-545, 2011.

W. Sandborn, Panes J 3 , Vranic I 4 Niezychowski W 6 ; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease, Clin Gastroenterol Hepatol, vol.12, issue.2 59, 2014.

J. Lopez, Grinspan A 1 . Fecal Microbiota Transplantation for Inflammatory Bowel Disease, Gastroenterol Hepatol, vol.12, issue.6, pp.374-383

W. Sandborn and B. Feagan, Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis, New England Journal of Medicine, vol.374, issue.18, pp.1754-62, 2016.
DOI : 10.1056/NEJMoa1513248